Article: Alcon's PATANASE(R) Nasal Spray Approved by FDA for Treatment of Nasal Allergy Symptoms.

HUENENBERG, Switzerland, April 15 /PRNewswire-FirstCall/ -- Alcon, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved PATANASE(R) (olopatadine hydrochloride) nasal spray for the relief of the symptoms of seasonal allergic rhinitis in patients 12 years of age and older. PATANASE(R) nasal spray, an extension to Alcon's market-leading ocular allergy product line, will be available in May of this year.

"We look forward to providing doctors the opportunity to prescribe PATANASE(R) to their patients who need and want a fast-acting nasal spray that quickly relieves symptoms," said Kevin Buehler, Alcon's senior vice president, global ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!